A Phase 1 study of CAP256J3LS in healthy adults
Completed Phase 1 NCT06585891
Study Description
A study to evaluate the safety of an antibody-based product (CAP256J3LS) for the potential prevention of HIV infection in healthy adults
Study Details
- Registry ID:
- NCT06585891
- Conditions:
- HIV Infection
- Phase:
- Phase 1
- Target Enrollment:
- 24 participants
- Start Date:
- Age Range:
- 18–60 years
- Healthy Volunteers:
- No
Study Locations (1 site)
-
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.